Skip to main content

Table 2 Clinical findings of CML patients responsive to imatinib therapy and a potential biomarker at the molecular response

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Total No Age (year) Duration on imatinib (month) IRIS molecular response (BCR-ABL1 ISa) Relative expressionb of hsa-miR-181a-5p (fold regulation) (collectively = 2.14 down-regulation)
16 25–75 26–122 MMR (≤ 0.1% or > 3-log reduction) −5.5987 to 1.2789
12 40–71 20–131 MR4 (≤ 0.01% BCR-ABL1IS or undetectable with 10,000–31,999 ABL1 transcripts) −8.664 to − 1.0906
2 32–54 24–50 MR4.5 (≤ 0.0032% BCR-ABL1IS or undetectable with 32,000–99,999 ABL1 transcripts) − 2.5939 and − 1.7594
30 25-75c
(47.87 ± 13.23)d
20-131c
(68.63 ± 31.95)d
  
  1. aInternational Scale
  2. bcomparing to control group
  3. cRange
  4. dmean ± sd